Abstract
In recent years, the worldwide cancer burden has increased dramatically. The treatment modalities for cancer are surgery, radiation therapy, and chemotherapy using anticancer drugs. Other treatment options include immunotherapy, stem cell transplantation, photodynamic therapy, etc. Even though available therapies offer a significant protective effect, scientists are still seeking a breakthrough in cancer treatment. One such therapeutic approach is radiopharmaceutical therapy, treating cancer with known medicinal radio compounds. Numerous radiopharmaceuticals with anticancer potential have a broad scope in cancer research and drug development. But, the development of a novel radiopharmaceutical must fulfil stringent regulatory criteria, which means that its physiochemical and biological qualities and therapeutic potential must be validated in animal models before it can be used in clinical trials. This chapter discusses the importance of radiopharmaceuticals, their dosimetry, biological properties, transition from diagnostic to therapeutic importance, challenges, animal models, preclinical assessment, and the recent advances that are being adopted in the field of radiopharmaceutical cancer research. Hence, this chapter will be very helpful for clinicians and researchers who are working with therapeutic radiopharmaceuticals.
This is a preview of subscription content, log in via an institution to check access.
References
Abbott M, Ustoyev Y (2019) Cancer and the immune system: the history and background of immunotherapy. Semin Oncol Nurs 35:150923. https://doi.org/10.1016/j.soncn.2019.08.002
Atli T, Sahin S, Arslan BU et al (2012) Comparison of the C14 urea breath test and histopathology in the diagnosis of helicobacter pylori in the elderly. J Pak Med Assoc 62:1061–1065
Baba K, Kaida H, Hattori C et al (2018) Tumoricidal effect and pain relief after concurrent therapy by strontium-89 chloride and zoledronic acid for bone metastases. Hell J Nucl Med 21:15–23. https://doi.org/10.1967/s002449910702
Ballinger JR (2005) Nomenclature of 99mTc-technetium-Labeled radiopharmaceuticals. J Nucl Med 46:2121
Behr TM, Béhé M, Stabin MG et al (1999) High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A fab’ fragments in a human colonic cancer model. Cancer Res 59:2635–2643
Beyer G-J, Miederer M, Vranjes-Durić S et al (2004) Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab. Eur J Nucl Med Mol Imaging 31:547–554. https://doi.org/10.1007/s00259-003-1413-9
Borrmann N, Friedrich S, Schwabe K et al (2013) Systemic treatment with 4-211Atphenylalanine enhances survival of rats with intracranial glioblastoma. Nuklearmedizin 52:212–221. https://doi.org/10.3413/Nukmed-0580-13-05
Brook I (2021) Early side effects of radiation treatment for head and neck cancer. Cancer Radiother 25:507–513. https://doi.org/10.1016/j.canrad.2021.02.001
Chan HS, Konijnenberg MW, Daniels T et al (2016) Improved safety and efficacy of (213) bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with L-lysine. EJNMMI Res 6:83. https://doi.org/10.1186/s13550-016-0240-5
Cheon D-J, Orsulic S (2011) Mouse models of cancer. Annu Rev Pathol 6:95–119. https://doi.org/10.1146/annurev.pathol.3.121806.154244
Correa-González L, Arteaga de Murphy C, Pichardo-Romero P et al (2014) (153)Sm-EDTMP for pain relief of bone metastases from prostate and breast cancer and other malignancies. Arch Med Res 45:301–308. https://doi.org/10.1016/j.arcmed.2014.03.006
Denk E, Hillegonds D, Hurrell RF et al (2007) Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass. J Bone Miner Res Off J Am Soc Bone Miner Res 22:1518–1525. https://doi.org/10.1359/jbmr.070617
Dikiy NP, Dovbnya AN, Lyashko Y V, et al (2008) Estimation of the absorbed doses of synthesized cisplatin with 195mPt in various organs of animals. Вопросы атомной науки и техники
Gallet M, Drouet C, Girodon F et al (2020) Effect of (99m)Tc elution in vivo from red cells on red cell volumes measured using autologous (99m)Tc-labeled red cells: comparison with (51)Cr method. Ann Biol Clin (Paris) 78:319–322. https://doi.org/10.1684/abc.2020.1547
Gao W, Liu L, Liu Z-Y et al (2009) Interstitial injection of (32)P-chromic phosphate during lung cancer resection to treat occult lymphatic metastasis. Nucl Med Commun 30:420–426. https://doi.org/10.1097/MNM.0b013e328310af19
Gillings N, Hjelstuen O, Ballinger J et al (2021) Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. EJNMMI Radiopharm Chem 6:8. https://doi.org/10.1186/s41181-021-00123-2
González García FM, Peinado Montes MA (2020) Dosimetry in therapeutic nuclear medicine: can we do it better? Rev Esp Med Nucl Imagen Mol 39:269–272
Herrero Álvarez N, Bauer D, Hernández-Gil J, Lewis JS (2021) Recent advances in Radiometals for combined imaging and therapy in cancer. ChemMedChem 16:2909–2941. https://doi.org/10.1002/cmdc.202100135
Herrmann K, Schwaiger M, Lewis JS et al (2020) Radiotheranostics: a roadmap for future development. Lancet Oncol 21:e146–e156. https://doi.org/10.1016/S1470-2045(19)30821-6
Hofman MS, Hicks RJ, Maurer T, Eiber M (2018) Prostate-specific membrane antigen PET: clinical utility in prostate cancer, Normal patterns, pearls, and pitfalls. Radiogr a Rev Publ Radiol Soc North Am Inc 38:200–217. https://doi.org/10.1148/rg.2018170108
Ilanchezhian M, Jha A, Pacak K, Del Rivero J (2020) Emerging treatments for advanced/metastatic Pheochromocytoma and Paraganglioma. Curr Treat Options in Oncol 21:85. https://doi.org/10.1007/s11864-020-00787-z
Jarvis P, Ho A, Sundram F (2021) Radium-223 therapy for metastatic castration-resistant prostate cancer: survival benefit when used earlier in the treatment pathway. Nucl Med Commun 42:332–336. https://doi.org/10.1097/MNM.0000000000001325
Kaneda-Nakashima K, Zhang Z, Manabe Y et al (2021) α-Emitting cancer therapy using 211At-AAMT targeting LAT1. Cancer Sci 112:1132–1140
Kassis AI (2008) Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med 38:358–366. https://doi.org/10.1053/j.semnuclmed.2008.05.002
Ku A, Facca VJ, Cai Z, Reilly RM (2019) Auger electrons for cancer therapy – a review. EJNMMI Radiopharm Chem 4:27. https://doi.org/10.1186/s41181-019-0075-2
Li HK, Morokoshi Y, Kodaira S et al (2021) Utility of 211At-Trastuzumab for the treatment of metastatic gastric cancer in the liver: evaluation of a preclinical α-Radioimmunotherapy approach in a clinically relevant mouse model. J Nucl Med 62:1468–1474
Li X, Lovell JF, Yoon J, Chen X (2020) Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol 17:657–674. https://doi.org/10.1038/s41571-020-0410-2
Liu Y, Watabe T, Kaneda-Nakashima K et al (2020) Preclinical evaluation of radiation-induced toxicity in targeted alpha therapy using [(211)at] NaAt in mice: a revisit. Transl Oncol 13:100757. https://doi.org/10.1016/j.tranon.2020.100757
Liu Y, Watabe T, Kaneda-Nakashima K et al (2022) Fibroblast activation protein targeted therapy using [(177) Lu]FAPI-46 compared with [(225)ac]FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging 49:871–880. https://doi.org/10.1007/s00259-021-05554-2
Minnix M, Li L, Yazaki PJ et al (2021) TAG-72-targeted α-radionuclide therapy of ovarian cancer using (225) ac-Labeled DOTAylated-huCC49 antibody. J Nucl Med 62:55–61. https://doi.org/10.2967/jnumed.120.243394
Mittra ES (2018) Neuroendocrine tumor therapy: (177) Lu-DOTATATE. AJR Am J Roentgenol 211:278–285. https://doi.org/10.2214/AJR.18.19953
Morris ZS, Wang AZ, Knox SJ (2021) The radiobiology of radiopharmaceuticals. Semin Radiat Oncol 31:20–27. https://doi.org/10.1016/j.semradonc.2020.07.002
Müller C, Umbricht CA, Gracheva N et al (2019) Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. Eur J Nucl Med Mol Imaging 46:1919–1930. https://doi.org/10.1007/s00259-019-04345-0
Nadar RA, Franssen GM, Van Dijk NWM et al (2021) Bone tumor-targeted delivery of theranostic (195m)Pt-bisphosphonate complexes promotes killing of metastatic tumor cells. Mater today Bio 9:100088. https://doi.org/10.1016/j.mtbio.2020.100088
Najafi M, Farhood B, Mortezaee K (2019) Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol 234:8381–8395. https://doi.org/10.1002/jcp.27740
Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223. https://doi.org/10.1056/NEJMoa1213755
Phaeton R, Jiang Z, Revskaya E et al (2016) Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer. Cancer Med 5:9–16. https://doi.org/10.1002/cam4.562
Pouget J-P, Constanzo J (2021) Revisiting the radiobiology of targeted alpha therapy. Front Med 8:692436. https://doi.org/10.3389/fmed.2021.692436
RADIOISOTOPES I, SERIES R (2021) Guidance for preclinical studies with radiopharmaceuticals
Schmitt A, Bernhardt P, Nilsson O et al (2003) Biodistribution and dosimetry of 177Lu-labeled [DOTA0, Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm 18:593–599. https://doi.org/10.1089/108497803322287682
Sgouros G (2019) Radiopharmaceutical therapy. Health Phys 116:175–178. https://doi.org/10.1097/HP.0000000000001000
Sgouros G, Goldenberg DM (2014) Radiopharmaceutical therapy in the era of precision medicine. Eur J Cancer 50:2360–2363. https://doi.org/10.1016/j.ejca.2014.04.025
Sgouros G, Hobbs RF, Abou DS (2014) The role of preclinical models in radiopharmaceutical therapy. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet e121–5. https://doi.org/10.14694/EdBook_AM.2014.34.e121
Sgouros G, Bodei L, McDevitt MR, Nedrow JR (2020) Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov 19:589–608. https://doi.org/10.1038/s41573-020-0073-9
Shen CJ, Minn I, Hobbs RF et al (2020) Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer. Theranostics 10:2888–2896. https://doi.org/10.7150/thno.38882
Soyluoglu S, Durmus-Altun G (2021) Animal models for the evaluation of Theranostic radiopharmaceuticals. Curr Radiopharm 14:15–22. https://doi.org/10.2174/1874471013666200425223428
St James S, Bednarz B, Benedict S et al (2021) Current status of radiopharmaceutical therapy. Int J Radiat Oncol Biol Phys 109:891–901. https://doi.org/10.1016/j.ijrobp.2020.08.035
Stefan Morariu D, Vlad C, Puscas ME et al (2020) Is there a place for F18-FDG PET/CT in the diagnosis of primary breast cancer? J BUON 25:605–611
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
Tan Z, Chen P, Schneider N et al (2012) Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice. Int J Oncol 40:1881–1888. https://doi.org/10.3892/ijo.2012.1357
Vermeulen K, Vandamme M, Bormans G, Cleeren F (2019) Design and challenges of radiopharmaceuticals. Semin Nucl Med 49:339–356. https://doi.org/10.1053/j.semnuclmed.2019.07.001
Watabe T, Kaneda-Nakashima K, Shirakami Y et al (2020) Targeted alpha therapy using astatine ((211) at)-labeled phenylalanine: a preclinical study in glioma bearing mice. Oncotarget 11:1388–1398. https://doi.org/10.18632/oncotarget.27552
Weeks S, Grossman CE (2022) 131 I Sodium Iodide. Treasure Island (FL)
Wilson T, Pirovano G, Xiao G et al (2021) PARP-targeted auger therapy in p53 mutant colon cancer xenograft mouse models. Mol Pharm 18:3418–3428. https://doi.org/10.1021/acs.molpharmaceut.1c00323
Wyszomirska A (2012) Iodine-131 for therapy of thyroid diseases. Physical and biological basis. Nucl Med Rev Cent East Eur 15:120–123
Zelenetz AD, Popplewell LL, Noy A et al (2020) Phase 2 study of Iodine-131 Tositumomab plus chemotherapy in patients with previously untreated mantle-cell lymphoma. Clin Lymphoma Myeloma Leuk 20:749–756.e1. https://doi.org/10.1016/j.clml.2019.04.010
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Singapore Pte Ltd.
About this entry
Cite this entry
Bari, A.B.A., Samuel, P.J., Rangasamy, S.S. (2022). Radiopharmaceuticals: A New Era in Cancer Therapy – Light on Initial Findings on Animal Model. In: Pathak, S., Banerjee, A., Bisgin, A. (eds) Handbook of Animal Models and its Uses in Cancer Research. Springer, Singapore. https://doi.org/10.1007/978-981-19-1282-5_49-1
Download citation
DOI: https://doi.org/10.1007/978-981-19-1282-5_49-1
Received:
Accepted:
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-1282-5
Online ISBN: 978-981-19-1282-5
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences